MASTMAX – Drostanolone Enanthate 200mg/ml 5x2ml Box
PHARMACEUTICAL NAME: Drostanolone Enanthate
MOLECULAR STRUCTURE: C27H44O3
PROPRIETARY NAME: MASTMAX
COMPOSITION: Each ml of MASTMAX contains 200 mg Drostanolone Enanthate in oil base
PHARMACOLOGICAL CLASSIFICATION: Anabolic Steroids
MASTMAX is having both androgenic and anabolic properties when administered parentally.
It is a highly androgenic, moderately anabolic and moderately antiestogenic compound. It is a synthetic derivative of dihydrotestosterone. It does not aromatize and therefore is not converted to estrogen. It is therefore necessary that the drug be administered with the prior consultation of the doctor and with prescription. MASTMAX has a receptor binding ability 3-5 times greater than that of testosterone. This means that the drug can hung out longer in androgen recepto-sites and is not easily displaced. The result should be increased AAS activity.
Contraindicated in infant, pregnancy & lactating mothers. Carcinoma of prostate and carcinoma of male breast. It is not intended for use in female patients other than those with disseminated breast cancer. Contraindicated in nephrosis or the nephrotic phase of nephritis, cardiac and renal failure, hypercalcaemia, oedema, jaundice, liver disease with impaired bilirubin excretion, testicular and hepatic carcinoma.
DOSAGE AND DIRECTIONS FOR USE:
MASTMAX injections should be administered intramusculary, preferably deep into the gluteal muscle.
Effective Dose Males – Intramuscular, 200 – 600 mg/week (2 mg/lb of Body weight)
Effective Dose Females – Intramuscular, 50 to 100 mg/week
Active life: 9 days
Rashes, cramps, dyspepsia. Virilisation which appears in sensitive women as hoarseness, acne, hirsutism, and increased libido and menstrual irregularities.
Patients with the following conditions should be monitored:
1) In cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions), since anabolic steroids may induce salt and fluid retention.
2) Diabetes, since anabolic steroids may improve the glucose tolerance and decrease the need for insulin or other antidiabetic drugs.
3) Incomplete statural growth, since anabolic steroids in high dosages may accelerate epiphyseal closure.
4) Skeletal metastases, since anabolic steroids may induce hypercalcemia and hypercalciuria in these patients.
5) Liver dysfunction.
6) If signs of virilization develops, treatment should be discontinued.
Potentiates corticosteroids. Potentiates oral anticoagulants, thereby enhancing bleeding tendency. Liver-enzyme-inducing agents may reduce the effects of MASTMAX by enhancing its metabolism in the liver.
It is not frequent because physician or other expert administers it. Acute intramuscular toxicity of MASTMAX is very low.
Store in a cool dry place below 25 °C.
Not to be refrigerated.
Protect from light.
Keep out of reach of children.
5 vials of 2 ml (200 mg/ml)
Pharmed Corporation Ltd., 3361/A, Rani Bagh, Mahindra Park Rajdhani Enclave, Shakurpur, New Delhi, Delhi 110034, India tel +919953242466, http://www.pharmed-corp.com
DATE OF PUBLICATION OF THIS PACKAGE INSERT: